Demjanjuk’s Family Appeal Decision on Death
The family of John Demjanjuk appealed the decision by German prosecutors to close an investigation into the convicted Nazi war criminal’s death.
Prosecutors in the German state of Bavaria late last month determined that Demjanjuk’s death was not hastened by medication administered at a nursing home in Bavaria. Demjanjuk died while he was awaiting an appeal of his conviction last year by a Munich court for his role in the murder of 27,900 people at the Sobibor camp in Poland.
Ulrich Busch, an attorney for Demjanjuk, filed an appeal on Tuesday that said the decision contradicts “all medical knowledge” about the drug Novalgin, which was used to treat Demjanjuk, according to The Associated Press. The drug is common in Germany but banned in the United States and other countries.
Busch had filed a complaint in May with German prosecutors asking them to open an investigation of five doctors and a nurse, alleging that the pain medication they gave to Demjanjuk added to his kidney problems. Demjanjuk died in March at 91.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
